St. Jude Children's Research Hospital

Julia Lea Hurwitz

Karen Slobod

Charles John Russell

Toru Takimoto

Christopher Coleclough

Allen Portner

Randall Owens

Randall J Owens

Karen S Slobod

The present invention relates to a Sendai virus or recombinant Sendai virus vector. In particular the present invention provides methods, vectors, formulations, compositions, and kits for a modified Enders strain Sendai viral vector. An immunogenic vector can be used in any in vitro or in vivo system. Moreover, some embodiments include vectors for imaging virus growth, location and transmission.

Modified Sendai virus vaccine and imaging vector

Polyenv vaccines are provided that comprise mixtures of at least 4 to about 10,000 different recombinant viruses that each express a different HIV env variant or a portion thereof containing both constant and variable regions, as well as methods of making and using such polyenv vaccines and viruses, including the use of the polyenv vaccine, in live, attenuated or inactivated form, for prophylaxis or treatment of HIV infection. The viral vaccines of the invention are optimally combined with a recombinant HIV env booster, or a recombinant HIV env gene DNA priming or boosting vaccine.

Preparation and use of viral vectors for mixed envelope protein vaccines against human immunodeficiency viruses

Bi-functional plasmid that can act as both a DNA vaccine and a

Polyenv immunogenic composition are provided that comprise mixtures of at least 4 different recombinant viruses that each express a different HIV env variant or a portion thereof containing both constant and variable regions, as well as methods of making and using such polyenv immunogenic composition and viruses. The immunogenic composition of the invention are optimally combined with a recombinant HIV env booster, or a recombinant HIV env gene DNA priming or boosting vaccine.

Preparation and use of viral vectors for mixed envelope protein

Polyenv vaccines are provided that comprise mixtures of at least 4-40 to about 10,000 different recombinant vaccinia viruses that each express a different HIV env variant or a portion thereof containing both constant and variable regions, as well as methods of making and using such polyenv vaccines and vaccinia viruses, including the use of the polyenv vaccine, in live, attenuated or inactivated form, for prophylaxis or treatment of HIV infection.

Growing community of inventors

Germantown, TN, United States of America

Julia Lea Hurwitz